Globe Life’s 20.2% return over the past six months has outpaced the S&P 500 by 9.3%, and its stock price has climbed to $171.06 per share. This performance may have investors wondering how to approach the situation.
Is there a buying opportunity in Globe Life, or does it present a risk to your portfolio? Get the full stock story straight from our expert analysts, it’s free.
Why Is Globe Life Not Exciting?
Despite the momentum, we’re passing on Globe Life for now. Here are three reasons why GL doesn’t excite us, plus one stock we’d rather own.
1. Long-Term Revenue Growth Disappoints
Insurers earn revenue three ways. The core insurance business itself, often called underwriting and represented in the income statement as premiums earned, is one way. Investment income from investing the “float” (premiums collected upfront not yet paid out as claims) in assets such as fixed-income assets and equities is the second way. Fees from various sources such as policy administration, annuities, or other value-added services are the third.
Over the last five years, Globe Life grew its revenue at a tepid 4.8% compounded annual growth rate. This was below our standard for the insurance sector.
2. Net Premiums Earned Point to Soft Demand
Net premiums earned are net of what’s paid to reinsurers (insurance for insurance companies), which are used by insurers to protect themselves from large losses.
Globe Life’s net premiums earned has grown at a 5% annualized rate over the last five years, worse than the broader insurance industry and in line with its total revenue.
3. Steady Increase in BVPS Highlights Solid Asset Growth
In the insurance industry, book value per share (BVPS) provides a clear picture of shareholder value, as it represents the total equity backing a company’s insurance operations and growth initiatives.
Although Globe Life’s BVPS declined at a 1.1% annual clip over the last five years, the good news is that its growth inflected positive over the past two years as BVPS grew at a solid 17.3% annual clip (from $58.06 to $79.89 per share).
Final Judgment
Globe Life’s business quality ultimately falls short of our standards. With its shares outperforming the market lately, the stock trades at 2× forward P/B (or $171.06 per share). While this valuation is fair, the upside isn’t great compared to the potential downside. We’re fairly confident there are better stocks to buy right now. Let us point you toward a top digital advertising platform riding the creator economy.
Stocks We Would Buy Instead of Globe Life
ONE MORE THING: Top 6 Stocks for This Week. This market is separating quality stocks from expensive ones fast. AI is taking down whole sectors with no warning. In a rotation this fast, you need more than a list of good companies.
Our AI system flagged Palantir before it ran 1,662% between October 2022 and February 2026. AppLovin before it ran 753% between February 2024 and February 2026. Nvidia before it ran 1,178% between January 2023 and February 2026. Each week it produces 6 new names that pass the same tests. Get Our Top 6 Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-small-cap company Comfort Systems (+1,154% between June 2020 and June 2025). Find your next big winner with StockStory today.
